Psychiatr. praxi 2018; 19(3): 106-110 | DOI: 10.36290/psy.2018.022

Mental symptoms in patients who suffer from multiple sclerosis

MUDr. Štěpánka Machová1, MUDr. Eva Kadlecová, CSc.2
1 Psychiatrická klinika FN a LF UK v Plzni
2 Psychiatrická ambulance, Písek

Multiple sclerosis is a severe demyelinating disease. The disease itself and the side effects of introduced pharmacotherapy canpossibly contribute to developing mental disorders in patients with multiple sclerosis. The most common mental symptoms presentingin multiple sclerosis patients is depression, anxiety, pathological crying and laughing, a cognitive deficit. Rarely, patientsmay present psychotic symptoms or mania. The aim of this article is to raise the awareness about significant yet often missedoccurrence of mental disorders in patients with multiple sclerosis. The article also lists the treatment options for these disorders.Timely and adequate treatment can significantly improve patients quality of life.

Keywords: multiple sclerosis, mental symptoms, pharmacotherapy, corticosteroids

Published: October 15, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Machová Š, Kadlecová E. Mental symptoms in patients who suffer from multiple sclerosis. Psychiatr. praxi. 2018;19(3):106-110. doi: 10.36290/psy.2018.022.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Marrie RA, Reingold S, Cohen J, et al. The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review. Multiple Sclerosis Journal; 2015; 21(3): 305-317. Go to original source... Go to PubMed...
    2. Havrdová E. Roztroušená skleróza. Farmakoterapie pro praxi. Praha: Jesenius Maxdorf; 2005: 12-64.
    3. Paparrigopoulos T, Ferentinos P, Kouzoupis A, et al. The neuropsychiatry of multiple sclerosis: Focus on disorders of mood, affect and behaviour. International Review of Psychiatry; 2010; 22(1): 14-21. Go to original source... Go to PubMed...
    4. Masopust J, Vališ M, Taláb R. Psychické příznaky roztroušené mozkomíšní sklerózy. Česká a slovenská psychiatrie; 2007; 1: 47-54.
    5. Anders M., Havrdová E., Herman E., Hovorka J., Mikulík R., Pěničková V., Roth J. Deprese v neurologické praxi. Praha: Galén; 2001: 5-10.
    6. Patten SB, Metz LM, Reimer MA. Biopsychosocial correlate of major depression in a multiple sclerosis population. Multiple sclerosis; 2000; 6: 115-120. Go to original source... Go to PubMed...
    7. Vachová M., Dušánková J., Zámečník L. Symptomatická léčba roztroušené sklerózy. Neurologie pro praxi; 2008; 9(4): 226-231.
    8. Feinstein A, Roy P, Lobaugh N, et. al. Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology; 2004; 62: 586-590. Go to original source... Go to PubMed...
    9. Galeazzi GM, Ferrari S, Giaroli G, et al. Psychiatric disorders and depression in multiple sclerosis outpatients: impact of disability and interferon beta therapy. Neurological Sciences; 2005; 26: 255-262. Go to original source...
    10. Fenstein A. Multiple sklerosis and depression. Multiple Sclerosis Journal; 2011; 17(11): 1276-1281. Go to original source... Go to PubMed...
    11. Schiffer RB, Wineman N, Weitkamp M, et al. Association between bipolar affective disorder and multiple sclerosis. American Yournal of Psychiatry; 1986; 143: 94-95. Go to original source...
    12. Fenstein A, du Boulay G, Ro, M.A. Psychotic illness in multiple sclerosis. A clinical and magnetic resonance paging study. British Journal of Psychiatry; 1992; 161: 680-685. Go to original source... Go to PubMed...
    13. Korostil M, Feistein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Multiple Sclerosis; 2007; 13: 67-72. Go to original source... Go to PubMed...
    14. Hoang H, Laursen B, Stenager EN, et al. Psychiatric co-morbidity in multiple sclerosis: The risk of depression and anxiety before and after MS diagnosis. Multiple Sclerosis Journal; 2016; 22(3): 347-353. Go to original source... Go to PubMed...
    15. Rabins PV. Euphoria in multiple sclerosis. In S. M. Rao (Ed.), Neurobehavioral aspects of multiple sclerosis; 1990; 180-185. New York: Oxford University Press.
    16. Fenstein A, O'Connor P, Gray T, et al. Pathological laughing and crying in multiple sclerosis: A preliminary report suggesting a role for the prefrontal cirtex. Multiple Sclerosis Yournal; 1999; 5: 69-73. Go to original source... Go to PubMed...
    17. Panitch H.S., Thisted R.A., Smith R.A., Wynn D.R., Wymer J.P., Achiron A. et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbr affect in multiple sclerosis. Annals of Neurology; 2006; 59: 780-787. Go to original source... Go to PubMed...
    18. Udaka F, Yamao S, Nagata H, et al. Pathological laughing and crying treated with levodopa. Archives of Neurology; 1984; 41: 1095-1096. Go to original source... Go to PubMed...
    19. Falk WE, Mahnke MW, Poskanzer DC. Lithium profylaxis of corticotropin-induced psychosis. JAMA; 1979; 241 (10): 1011-1012. Go to original source...
    20. Chong SA, Ko SM. Clozapine treatment of psychosis associated with multiple sclerosis. Can. J. Psychiatry; 1997; 42: 90-91. Go to original source...
    21. Yong VW. Prospects for neuroprotection in multiple sclerosis. Front. Biosci; 2004; 9: 864-872. Go to original source... Go to PubMed...
    22. Polman Ch, O'Connor P, Havrdová E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910. Go to original source...
    23. Kappos L, Radue EM, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401. Go to original source...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.